Medincell's partner teva provides new update on pivotal clinical phase 3 of investigational olanzapine long-acting injectable (lai)

Montpellier, france--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), announced during the 22nd annual global healthcare conference held yesterday that c.99% of the targeted injections for submission have been performed as of today (replay available here). teva also confirmed that the full submission safety results are expected to be available in h2 24. olanzapine lai is an investigational once-monthly subcutaneous long-acting.
TEVA Ratings Summary
TEVA Quant Ranking